Show simple item record

dc.contributor.authorHerrera Barragán, Liliana
dc.contributor.authorEsquivel Areiza, Linda Jhoana
dc.contributor.authorMariño, María Liliana
dc.date.accessioned2020-01-08T19:36:23Z
dc.date.available2020-01-08T19:36:23Z
dc.date.issued2016-06-16
dc.identifierhttp://revistas.unimilitar.edu.co/index.php/rmed/article/view/2337
dc.identifier10.18359/rmed.2337
dc.identifier.urihttp://hdl.handle.net/10654/34479
dc.descriptionBullous morphea is an infrequent type of morphea, for this reason there is not much evidence on the literature about the best treatment for this condition. We introduce the case of a 10 years old child with a bullous morphea diagnosis; she was successfully treated with phototherapy, calcipotriene and superoxide dismutase.eng
dc.descriptionLa morfea ampollosa es un tipo infrecuente de morfea, por esta razón existe poca evidencia en la literatura acerca del mejor tratamiento para esta patología. Presentamos el caso de una niña de 10 años a quien se le realizó un diagnóstico de morfea ampollosa, y fue tratada exitosamente con fototerapia UVA-1, calcipotriol y superóxido dismutasa.spa
dc.description Morfea bolhosa é um tipo de morphea infreqüente, por isso não há muita evidência na literatura sobre o melhor tra­tamento para esta condição. Apresentamos o caso de uma criança de 10 anos com diagnóstico de morféia bolhosa; Ela foi tratada com sucesso com fototerapia, calcipotriol e superóxido-dismutasepor
dc.formatapplication/pdf
dc.language.isospa
dc.publisherUniversidad Militar Nueva Granadaspa
dc.rightsDerechos de autor 2016 Revista Medspa
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0spa
dc.sourceRevista Med; Vol. 24 Núm. 1 (2016); 97-101spa
dc.source1909-7700
dc.source0121-5256
dc.titleBullous morpheaeng
dc.titleMorfea Ampollosa tratamiento exitoso con fototerapia UVA 1, calcipotriol y superóxido dismutasa tópico, reporte de un casospa
dc.titleMorfe de bullopor
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.referenceshttp://revistas.unimilitar.edu.co/index.php/rmed/article/view/2337/2423
dc.relation.references/*ref*/Fett and Werth. Update on morphea, Part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. February 2011;64:217-28.
dc.relation.references/*ref*/Marsol B. Update on the Classification and Treatment of Localized Scleroderma. Actas Dermosifiliogr. 2013;104(8):654-666.
dc.relation.references/*ref*/Yasar S, Mumcuoglu C, Serdar Z, Gunes P. Case of Lichen Sclerosus et Atrophicus Accompanying Bullous Morphea. Ann Dermatol. 2011; Vol. 23, Suppl. 3: S354-S355.http://dx.doi.org/10.5021/ad.2011.23.S3.S354
dc.relation.references/*ref*/Zwischenberger and Jacobe. A systematic review of morphea treatments and therapeutic algorithm, J Am Acad Dermatol, Nov 2011; volume 65, number 5.
dc.relation.references/*ref*/Jia H, Chen X, Chi J, Zhao C, Cao Y, Zeng X, Chen X, Nanjing. A case of Bullous morphea reported in mainland China, International Journal of Dermatology. 2002; 41, 948-950.http://dx.doi.org/10.1046/j.1365-4362.2002.16672.x
dc.relation.references/*ref*/Martin L, Kirsner R. Ulcers caused by bullous morphea treated with tissue-engineered skin. Dermatologic surgery. International Journal of Dermatology. 2003; 42, 402–404.http://dx.doi.org/10.1046/j.1365-4362.2003.01763.x
dc.relation.references/*ref*/Fiala K, Wells M, Mullinax K, Stetson C, Paulger B. Linear Morphea Presenting as Acquired Unilateral Edema. Pediatric Dermatology. 2007; Vol. 24 No. 2 147–150.http://dx.doi.org/10.1111/j.1525-1470.2007.00363.x
dc.relation.references/*ref*/Kavala M, Zindanci I, Demirkesen C, Beyhan E, Torkoglu Z. Intertriginous bullous morphea: A clue for the pathogenesis. Indian J Dermatol Venereol Leprol. July August 2007; Vol 73, Issue 4.
dc.relation.references/*ref*/Kreuter A, Hyun J, Stücker M, Sommer A, Altmeyer P, Gambichler T, A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized Scleroderma, J Am Acad Dermatol. March 2006; volume 54, number 3.http://dx.doi.org/10.1016/j.jaad.2005.11.1063
dc.relation.references/*ref*/Gambichler T, Terras S, Kreuter A, Treatment regimens, protocols, dosage, and indications for UVA1 phototherapy: Facts and controversies. Clinics in Dermatology. 2013; 31, 438–454.http://dx.doi.org/10.1016/j.clindermatol.2013.01.011
dc.relation.references/*ref*/Sator P, Radakovic S, Schulmeister K, Hönigsmann H, Tanew A. Medium-dose is more effective than low-dose ultraviolet A1 phototherapy for localized scleroderma as shown by 20-MHz ultrasound assessment. J Am Acad Dermatol. May 2009;Volume 60;number 5;786-791.http://dx.doi.org/10.1016/j.jaad.2008.12.013
dc.relation.references/*ref*/Kroft E, Berkhof N, Van de Kerkhof P, Gerritsen R, Jong E, Ultraviolet A phototherapy for sclerotic skin diseases: A systematic review. J Am Acad Dermatol 2008; volume 59, number 6, 1017-1030.http://dx.doi.org/10.1016/j.jaad.2008.07.042
dc.relation.references/*ref*/Cunningham B, Landells I, Langman C, Sailer D, Paller A. Topical calcipotriene for morphea/linear scleroderma. Journal of the American Academy of Dermatology. August 1998;39:211-5.http://dx.doi.org/10.1016/S0190-9622(98)70077-5
dc.relation.references/*ref*/Jablonska S, Blaszczyk M, Scleroderma and Sclerotic Skin Conditions: Unapproved Treatments. Clinics in Dermatology Y 2002;20:634–637.http://dx.doi.org/10.1016/S0738-081X(02)00283-3
dc.relation.references/*ref*/Shahriari M, Kerr P, Slade K, Grant-Kels J. Vitamin D and the skin. Clinics in Dermatology. 2010; 28: 663–668.http://dx.doi.org/10.1016/j.clindermatol.2010.03.030
dc.relation.references/*ref*/Parish J, Topical Vitamin D3 Analogues: Unapproved Uses, Dosages, or Indications. Clinics in Dermatology Y 2002;20:558–562.http://dx.doi.org/10.1016/S0738-081X(02)00269-9
dc.relation.references/*ref*/Nagai M, Hasegawa M, Takehara K, Sato S. Novel Autoantibody to Cu/Zn Superoxide Dismutase in Patients with Localized Scleroderma. J Invest Dermatol. 2004:122:594 –601.http://dx.doi.org/10.1111/j.0022-202X.2004.22333.x
dc.relation.references/*ref*/Jinnin M, Ihn H, Yazawa N, Asano Y, Yamane K, Tamaki K. Serum levels of manganese superoxide dismutase in patients with localized scleroderma. Exp Dermatol. 2004: 13: 357–360.http://dx.doi.org/10.1111/j.0906-6705.2004.00160.x
dc.relation.references/*ref*/Treiber N, Peters T, Sindrilaru A, Huber R, Kohn M, Menke A, Briviba K, Kreppel F, Basu A, Maity P, Koller M, Iben S, Wlaschek M, Kochanek S, Scharffetter-Kochane K. Overexpression of manganese superoxide dismutase in human dermal fibroblasts enhances the contraction of free floating collagen lattice: implications for ageing and hyperplastic scar formation. Arch Dermatol Res. 2009: 301:273–287.http://dx.doi.org/10.1007/s00403-009-0935-9
dc.relation.references/*ref*/Storz and Imlay. Oxidative stress. Current Opinion in Microbiology 1999, 2:188-l 94.
dc.subject.proposalBullous morpheaeng
dc.subject.proposalphototherapyeng
dc.subject.proposalcalcipotrieneeng
dc.subject.proposalsuperoxide dismutaseeng
dc.subject.proposalMorfea ampollosaspa
dc.subject.proposalFototerapiaspa
dc.subject.proposalCalcipotriolspa
dc.subject.proposalSuperoxido dismutasaspa
dc.subject.proposalMorfeta bolhosapor
dc.subject.proposalfototerapiapor
dc.subject.proposalcalcipotriolpor
dc.subject.proposalsuperóxido dismutasepor


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record